Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Shattuck Labs, Inc. - Common Stock
(NQ:
STTK
)
3.522
+0.163 (+4.84%)
Streaming Delayed Price
Updated: 2:39 PM EDT, Aug 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
91,596
Open
3.370
Bid (Size)
3.510 (2)
Ask (Size)
3.530 (3)
Prev. Close
3.360
Today's Range
3.320 - 3.530
52wk Range
1.330 - 11.76
Shares Outstanding
42,122,778
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Assessing Shattuck Labs: Insights From 7 Financial Analysts
August 02, 2024
Via
Benzinga
STTK Stock Earnings: Shattuck Labs Misses EPS, Beats Revenue for Q2 2024
August 01, 2024
STTK stock results show that Shattuck Labs missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Performance
YTD
-53.41%
-53.41%
1 Month
-19.94%
-19.94%
3 Month
-52.72%
-52.72%
6 Month
-61.59%
-61.59%
1 Year
+59.39%
+59.39%
More News
Read More
Shattuck Labs Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 01, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference
July 30, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Assessing Shattuck Labs: Insights From 6 Financial Analysts
June 14, 2024
Via
Benzinga
Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes
July 01, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Workday To Rally Over 52%? Here Are 10 Top Analyst Forecasts For Thursday
June 20, 2024
Via
Benzinga
Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid
June 14, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML)
June 10, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk
June 06, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the
May 14, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
STTK Stock Earnings: Shattuck Labs Beats EPS, Beats Revenue for Q1 2024
May 02, 2024
Via
InvestorPlace
Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 02, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
April 09, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference
April 01, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors
March 04, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights
February 29, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Announces Participation in Upcoming March Conferences
February 26, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases
February 13, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
January 19, 2024
Via
Benzinga
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2024
January 08, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
January 08, 2024
Via
Benzinga
Shattuck Labs Announces Presentation at Upcoming 42nd Annual J.P. Morgan Healthcare Conference
January 04, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Announces $50 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants
December 21, 2023
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
December 15, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.